# Vopimetostat PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vopimetostat

> The next catalyst for vopimetostat, sponsored by Tango Therapeutics, Inc. (TNGX), is its trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for vopimetostat?

The next catalyst for vopimetostat, sponsored by Tango Therapeutics, Inc. (TNGX), is its trial start, 1H 2027. Press release filed with the SEC (EX-99): ""Following discussions with the U.S. FDA, we are focused on initiating a planned registrational Phase 3 trial of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer in the first half of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/vopimetostat)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-429423, https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa/vopimetostat#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | vopimetostat |
| Codes | TNG462 |
| Sponsor | Tango Therapeutics, Inc. (TNGX) https://sec-api.dev/companies/tngx/catalysts |
| Indications | mtap-wild type pancreatic cancer, mtap-deleted and ras-mutant metastatic pancreatic ductal adenocarcinoma |
| Modality | small_molecule |
| FDA designations | fast track, orphan |

## Timeline

### Jul 2023: trial start

- Status: completed. Date confidence: month.
- First seen 2026-03-05, last confirmed 2026-03-05.
- SEC Form 10-K (accession 0001193125-26-092518): "The first patient was dosed in July 2023 and we are currently enrolling patients at 250 mg QD." https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm

### Jun 2026: trial start

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-03-05, last confirmed 2026-06-10.
- SEC prospectus (424B) (accession 0001193125-26-266074): "In June 2026, we announced our plans to initiate a Phase 3 clinical trial of vopimetostat in combination with daraxonrasib in front-line pancreatic cancer." https://www.sec.gov/Archives/edgar/data/1819133/000119312526266074/d151329d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-261771): "In June 2026, we announced our plans to initiate a Phase 3 clinical trial of vopimetostat in combination with daraxonrasib in front-line pancreatic cancer." https://www.sec.gov/Archives/edgar/data/1819133/000119312526261771/d151329d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-092535): "The company is on track to initiate a pivotal study for vopimetostat monotherapy in 2L MTAP-del pancreatic cancer, with initiation anticipated in 2026." https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/tngx-ex99_1.htm

### June 8, 2026: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 1/2.
- First seen 2025-11-04, last confirmed 2026-06-08.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-260679): "BOSTON, June 8, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive initial data from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination with Revolution Medicines' RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC)." https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/d158334dex991.htm
- SEC Form 10-K (accession 0001193125-26-092518): "We have, for example, noted that in 2026 we will provide a clinical update on the lung cohort of the vopimetostat monotherapy clinical trial and initial data from the Phase 1/2 combination clinical trial with RAS(ON) inhibitors from RevMed." https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-263684): "Initial data from the Phase 1/2 study are anticipated in 2026." https://www.sec.gov/Archives/edgar/data/1819133/000119312525263684/tngx-ex99_1.htm

### 1H 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 3. Indication: MTAP-wild type pancreatic cancer.
- First seen 2026-10-23, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-429423): ""Following discussions with the U.S. FDA, we are focused on initiating a planned registrational Phase 3 trial of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613dex991.htm
- SEC Form 10-Q (accession 0001193125-26-452634): "In particular, we plan to initiate a global, randomized registrational trial evaluating the combination of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted PDAC in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1819133/000119312526452634/tngx-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-452635): "In October 2026, the Company announced that it plans to initiate a Phase 1/2 combination study of vopimetostat plus panRAS inhibitors in patients with MTAP-wild type pancreatic cancer in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1819133/000119312526452635/tngx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-452634): "In October 2026, we also disclosed that we plan to initiate a Phase 1/2 vopimetostat + RAS combination study in second-line MTAP-wild type PDAC in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1819133/000119312526452634/tngx-20260930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vopimetostat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vopimetostat PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vopimetostat

```bibtex
@misc{secapidev_pdufa_vopimetostat_20261116,
  title        = {Vopimetostat PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vopimetostat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vopimetostat_20261116","title":"Vopimetostat PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vopimetostat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
